McCormick & vs Danone SA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

McCormick & Company Incorporated (MKC)

Q3 202629 Jun – 21 Jul 2026

▼2▲1

McCormick's $45B Unilever deal drives 50% share plunge and regulatory review

$15.7B Unilever deal crushes shares 50% on leverage fears McCormick's $15.7 billion cash-and-stock purchase of Unilever's food business pushes debt to 4x EBITDA, above its target. Investors fear the huge price paid and heavy borrowing, sending shares down 50% from record highs.
This is the core new event explaining the massive share decline and investor concern.
Reverse Morris Trust structure dilutes existing shareholders The deal uses a Reverse Morris Trust, meaning McCormick issues about $29.1 billion in new shares. Unilever holders end up with roughly 65% of the combined company, leaving current McCormick owners with only 35% and heavy debt.
Explains the mechanics of dilution that directly pressure the stock price.
Berkshire Hathaway interest could ease financing burden Reports suggest Berkshire's new CEO Greg Abel might invest, potentially financing the $16 billion cash need via preferred stock. McCormick's low 9x P/E and 3.7% yield make it attractive, offering a possible counterweight to the selloff.
Provides a real positive counterweight that could support the stock if financing worries ease.
UK regulator opens review, adding deal uncertainty The UK competition watchdog is seeking comments on the merger until August 5. Regulatory scrutiny could delay or alter the deal, keeping a cloud over McCormick shares until the review concludes.
New regulatory hurdle adds uncertainty that can weigh on the stock in the near term.

July 202629 Jun – 21 Jul 2026

▼2▲1

McCormick's $45B Unilever deal drives 50% share plunge and regulatory review

$15.7B Unilever deal crushes shares 50% on leverage fears McCormick's $15.7 billion cash-and-stock purchase of Unilever's food business pushes debt to 4x EBITDA, above its target. Investors fear the huge price paid and heavy borrowing, sending shares down 50% from record highs.
This is the core new event explaining the massive share decline and investor concern.
Reverse Morris Trust structure dilutes existing shareholders The deal uses a Reverse Morris Trust, meaning McCormick issues about $29.1 billion in new shares. Unilever holders end up with roughly 65% of the combined company, leaving current McCormick owners with only 35% and heavy debt.
Explains the mechanics of dilution that directly pressure the stock price.
Berkshire Hathaway interest could ease financing burden Reports suggest Berkshire's new CEO Greg Abel might invest, potentially financing the $16 billion cash need via preferred stock. McCormick's low 9x P/E and 3.7% yield make it attractive, offering a possible counterweight to the selloff.
Provides a real positive counterweight that could support the stock if financing worries ease.
UK regulator opens review, adding deal uncertainty The UK competition watchdog is seeking comments on the merger until August 5. Regulatory scrutiny could delay or alter the deal, keeping a cloud over McCormick shares until the review concludes.
New regulatory hurdle adds uncertainty that can weigh on the stock in the near term.

Latest29 Jun – 21 Jul 2026

▼2▲1

McCormick's $45B Unilever deal drives 50% share plunge and regulatory review

$15.7B Unilever deal crushes shares 50% on leverage fears McCormick's $15.7 billion cash-and-stock purchase of Unilever's food business pushes debt to 4x EBITDA, above its target. Investors fear the huge price paid and heavy borrowing, sending shares down 50% from record highs.
This is the core new event explaining the massive share decline and investor concern.
Reverse Morris Trust structure dilutes existing shareholders The deal uses a Reverse Morris Trust, meaning McCormick issues about $29.1 billion in new shares. Unilever holders end up with roughly 65% of the combined company, leaving current McCormick owners with only 35% and heavy debt.
Explains the mechanics of dilution that directly pressure the stock price.
Berkshire Hathaway interest could ease financing burden Reports suggest Berkshire's new CEO Greg Abel might invest, potentially financing the $16 billion cash need via preferred stock. McCormick's low 9x P/E and 3.7% yield make it attractive, offering a possible counterweight to the selloff.
Provides a real positive counterweight that could support the stock if financing worries ease.
UK regulator opens review, adding deal uncertainty The UK competition watchdog is seeking comments on the merger until August 5. Regulatory scrutiny could delay or alter the deal, keeping a cloud over McCormick shares until the review concludes.
New regulatory hurdle adds uncertainty that can weigh on the stock in the near term.

Q2 202623 Jun – 26 Jun 2026

▲2▼1

McCormick's strong Q2 earnings beat, but Unilever deal overpay concerns linger

Q2 earnings beat and margin expansion McCormick reported Q2 adjusted EPS of $0.80, beating estimates, with sales up 14% and gross margin expanding 270 basis points. This shows the business is performing better than expected, which pushes the stock up.
This is the main new positive event that directly lifted the stock.
Reaffirmed 2026 outlook Management reaffirmed full-year adjusted EPS guidance of $3.05 to $3.13 and sales growth of 13-17%, including the Mexico acquisition. Reassuring guidance reduces uncertainty and supports the stock price.
Guidance reaffirmation is a key new factor that gives investors confidence.
Unilever deal overpay concerns persist Jim Cramer said McCormick is still reeling from its acquisition of Unilever's food business, which Wall Street views as a colossal overpay. This concern weighs on the stock, as investors worry about the high price paid.
This is a major ongoing negative force that explains why the stock remains under pressure despite good earnings.

June 202623 Jun – 26 Jun 2026

▲2▼1

McCormick's strong Q2 earnings beat, but Unilever deal overpay concerns linger

Q2 earnings beat and margin expansion McCormick reported Q2 adjusted EPS of $0.80, beating estimates, with sales up 14% and gross margin expanding 270 basis points. This shows the business is performing better than expected, which pushes the stock up.
This is the main new positive event that directly lifted the stock.
Reaffirmed 2026 outlook Management reaffirmed full-year adjusted EPS guidance of $3.05 to $3.13 and sales growth of 13-17%, including the Mexico acquisition. Reassuring guidance reduces uncertainty and supports the stock price.
Guidance reaffirmation is a key new factor that gives investors confidence.
Unilever deal overpay concerns persist Jim Cramer said McCormick is still reeling from its acquisition of Unilever's food business, which Wall Street views as a colossal overpay. This concern weighs on the stock, as investors worry about the high price paid.
This is a major ongoing negative force that explains why the stock remains under pressure despite good earnings.

23 Jun – 26 Jun 2026

▲2▼1

McCormick's strong Q2 earnings beat, but Unilever deal overpay concerns linger

Q2 earnings beat and margin expansion McCormick reported Q2 adjusted EPS of $0.80, beating estimates, with sales up 14% and gross margin expanding 270 basis points. This shows the business is performing better than expected, which pushes the stock up.
This is the main new positive event that directly lifted the stock.
Reaffirmed 2026 outlook Management reaffirmed full-year adjusted EPS guidance of $3.05 to $3.13 and sales growth of 13-17%, including the Mexico acquisition. Reassuring guidance reduces uncertainty and supports the stock price.
Guidance reaffirmation is a key new factor that gives investors confidence.
Unilever deal overpay concerns persist Jim Cramer said McCormick is still reeling from its acquisition of Unilever's food business, which Wall Street views as a colossal overpay. This concern weighs on the stock, as investors worry about the high price paid.
This is a major ongoing negative force that explains why the stock remains under pressure despite good earnings.

Danone SA (BN.PA)

Q3 202622 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.

July 202622 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.

Latest22 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.